Literature DB >> 8318901

Substrate specificities of catalytic fragments of protein tyrosine phosphatases (HPTP beta, LAR, and CD45) toward phosphotyrosylpeptide substrates and thiophosphotyrosylated peptides as inhibitors.

H Cho1, R Krishnaraj, M Itoh, E Kitas, W Bannwarth, H Saito, C T Walsh.   

Abstract

The transmembrane PTPase HPTP beta differs from its related family members in having a single rather than a tandemly duplicated cytosolic catalytic domain. We have expressed the 354-amino acid, 41-kDa human PTP beta catalytic fragment in Escherichia coli, purified it, and assessed catalytic specificity with a series of pY peptides. HPTP beta shows distinctions from the related LAR PTPase and T cell CD45 PTPase domains: it recognizes phosphotyrosyl peptides of 9-11 residues from lck, src, and PLC gamma with Km values of 2, 4, and 1 microM, some 40-200-fold lower than the other two PTPases. With kcat values of 30-205 s-1, the catalytic efficiency, kcat/Km, of the HPTP beta 41-kDa catalytic domain is very high, up to 5.7 x 10(7) M-1 s-1. The peptides corresponding to PLC gamma (766-776) and EGFR (1,167-1,177) phosphorylation sites were used for structural variation to assess pY sequence context recognition by HPTP beta catalytic domain. While exchange of the alanine residue at the +2 position of the PLC gamma (Km of 1 microM) peptide to lysine or aspartic acid showed little or no effect on substrate affinity, replacement by arginine increased the Km 35-fold. Similarly, the high Km value of the EGFR pY peptide (Km of 104 microM) derives largely from the arginine residue at the +2 position of the peptide, since arginine to alanine single mutation at the -2 position of the EGFR peptide decreased the Km value 34-fold to 3 microM. Three thiophosphotyrosyl peptides have been prepared and act as substrates and competitive inhibitors of these PTPase catalytic domains.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318901      PMCID: PMC2142405          DOI: 10.1002/pro.5560020611

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  23 in total

1.  Tyr527 is phosphorylated in pp60c-src: implications for regulation.

Authors:  J A Cooper; K L Gould; C A Cartwright; T Hunter
Journal:  Science       Date:  1986-03-21       Impact factor: 47.728

2.  An improved procedure for identifying and quantitating protein phosphatases in mammalian tissues.

Authors:  P Cohen; S Klumpp; D L Schelling
Journal:  FEBS Lett       Date:  1989-07-03       Impact factor: 4.124

3.  Neoplastic transformation induced by an activated lymphocyte-specific protein tyrosine kinase (pp56lck).

Authors:  J D Marth; J A Cooper; C S King; S F Ziegler; D A Tinker; R W Overell; E G Krebs; R M Perlmutter
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

4.  Purification of the major protein-tyrosine-phosphatases of human placenta.

Authors:  N K Tonks; C D Diltz; E H Fischer
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

5.  Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics.

Authors:  C Bialojan; A Takai
Journal:  Biochem J       Date:  1988-11-15       Impact factor: 3.857

6.  Affinity purification of newly phosphorylated protein molecules. Thiophosphorylation and recovery of histones H1, H2B, and H3 and the high mobility group protein HMG-1 using adenosine 5'-O-(3-thiotriphosphate) and cyclic AMP-dependent protein kinase.

Authors:  I Y Sun; E M Johnson; V G Allfrey
Journal:  J Biol Chem       Date:  1980-01-25       Impact factor: 5.157

7.  Identification of insulin receptor tyrosine residues autophosphorylated in vitro.

Authors:  H E Tornqvist; M W Pierce; A R Frackelton; R A Nemenoff; J Avruch
Journal:  J Biol Chem       Date:  1987-07-25       Impact factor: 5.157

8.  Adenosine 5'-O(3-thiotriphosphate) in the control of phosphorylase activity.

Authors:  D Gratecos; E H Fischer
Journal:  Biochem Biophys Res Commun       Date:  1974-06-18       Impact factor: 3.575

9.  Structural variants of human T200 glycoprotein (leukocyte-common antigen).

Authors:  S J Ralph; M L Thomas; C C Morton; I S Trowbridge
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

10.  A new member of the immunoglobulin superfamily that has a cytoplasmic region homologous to the leukocyte common antigen.

Authors:  M Streuli; N X Krueger; L R Hall; S F Schlossman; H Saito
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  7 in total

1.  Defining SH2 domain and PTP specificity by screening combinatorial peptide libraries.

Authors:  Anne-Sophie Wavreille; Mathieu Garaud; Yanyan Zhang; Dehua Pei
Journal:  Methods       Date:  2007-07       Impact factor: 3.608

2.  Identification of p130(cas) as a substrate for the cytosolic protein tyrosine phosphatase PTP-PEST.

Authors:  A J Garton; A J Flint; N K Tonks
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

3.  [Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases.

Authors:  S Desmarais; R W Friesen; R Zamboni; C Ramachandran
Journal:  Biochem J       Date:  1999-01-15       Impact factor: 3.857

4.  Protein phosphorylation by semisynthesis: from paper to practice.

Authors:  Lawrence M Szewczuk; Mary Katherine Tarrant; Philip A Cole
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

5.  Caged O-phosphorothioyl amino acids as building blocks for Fmoc-based solid phase peptide synthesis.

Authors:  Andreas Aemissegger; Christina N Carrigan; Barbara Imperiali
Journal:  Tetrahedron       Date:  2007-07-02       Impact factor: 2.457

Review 6.  Insulin receptor-associated protein tyrosine phosphatase(s): role in insulin action.

Authors:  P G Drake; B I Posner
Journal:  Mol Cell Biochem       Date:  1998-05       Impact factor: 3.842

7.  Differential Regulation of CD45 Expression on Granulocytes, Lymphocytes, and Monocytes in COVID-19.

Authors:  Muhammad G T Ahmed; Andreas Limmer; Christoph Sucker; Khaled Mohamed Fares; Sahar Abdel-Baky Mohamed; Ahmed H Othman; Marc Moritz Berger; Thorsten Brenner; Matthias Hartmann
Journal:  J Clin Med       Date:  2022-07-20       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.